Quelles sont les heures d'ouverture ?

Lundi 09:30 - 18:00 Mardi 09:30 - 18:00 Mercredi 09:30 - 18:00 Jeudi 09:30 - 18:00 Vendredi 09:30 - 18:00

Ad Scientiam_US

Page d'Accueil
France
Paris
Ad Scientiam_US

Informations de contact, plan et itinéraire, formulaire de contact, heures d'ouverture, services, évaluations, photos, vidéos et annonces de Ad Scientiam_US, Santé, 21-23 Rue Albert Bayet, Paris.

12/08/2025

🔬 DOMYA: our validation study for ME&MG is underway!

We have launched DOMYA, a one-year international clinical study designed to scientifically validate the performance of our Software as a Medical Device (SaMD) ME&MG, dedicated to monitoring persons with myasthenia gravis.

👩‍⚕️👨‍⚕️ Participants were recruited from specialized centers with the goal of comparing our new digital biomarkers to standard clinical reference measures.

🌍 The study is being conducted in both France and the United States, with a target of 94 enrolled patients.

DOMYA marks a key milestone in demonstrating the effectiveness and reliability of our technology in a real clinical environment.

📢 We look forward to sharing the first results very soon!

29/07/2025

🧪 What is a Decentralized Clinical Trial (DCT)?

According to AFCROs, over 80% of major clinical trials are delayed due to recruitment issues, and 70% of patients live more than two hours away from investigative sites.

This is why a decentralized trial, where certain steps take place outside the hospital, for example from home or a nearby care center, is so important.

👉 Thanks to mobile apps and digital health technologies (DHTs), patients can be monitored remotely and in real time.

✨ Why does it matter?

✅ Includes patients in rural or hard-to-reach areas

✅ More flexibility, better engagement & fewer dropouts

✅ Fewer missing data

✅ Larger, more diverse, multi-center trials

💡 A new way to move research forward — closer to patients.

17/07/2025

📣 ME&MGopen: an innovative study and a collective success!

The curtain falls on ME&MGopen, our very first decentralized clinical study... and a true collective achievement! 🙌

This unique study allowed people living with myasthenia gravis to complete 5 digital tests directly from their phone, at home, over the course of one year. 📱

🎯 Objective: Explore the feasibility of using a digital tool to better understand how myasthenia symptoms impacts patients’ daily lives.

👥 236 patients were enrolled and 156 had reached one year of follow-up

Among them:

👩 106 women

👨 50 men

🌎 2 countries: Canada 🇨🇦 & United States 🇺🇸

A heartfelt thank you to all participants for their trust and commitment 💚

The results of this study will be presented at several international conferences in the coming months.

Every participation matters in advancing research!

19/06/2025

💬 5 things we (often) don’t know about Myasthenia Gravis 👀

This rare neuromuscular disease is still poorly understood…

Here are 5 surprising facts worth rediscovering 👇

1️⃣ The disease can progress through unpredictable flare-ups.

MG is a fluctuating disease by its nature, symptoms are not constant and hardly predictable. Some periods are rather calm, others marked by severe fatigue or increased weakness. These fluctuations make daily life hard to anticipate.

2️⃣ It can be associated with other autoimmune diseases.

Myasthenia can coexist with other autoimmune conditions, sometimes making diagnosis and management more complex.

3️⃣ Some treatments may lose effectiveness over time.

Available treatments help improve quality of life, but their effectiveness can decrease. This often requires therapeutic adjustments.

4️⃣ Early signs often go unnoticed.

A drooping eyelid, unusual fatigue, difficulty speaking or swallowing... These subtle signs can delay diagnosis, especially since they vary throughout the day.

5️⃣ Gentle physical activity can be beneficial.

When physical activity is adapted, supervised, and regular, it can help keep muscles active, improve breathing, and support morale. A real plus in managing the disease 💚

📌 June is Myasthenia Awareness Month: the perfect time to talk about it, share, and support research 🧠✨

📚 Sources:
AFM-Téléthon – Autoimmune Myasthenia
MSD Manuals – Myasthenia Gravis

11/06/2025

📌 5 things to know about myasthenia gravis

1️⃣ It is a rare autoimmune neuromuscular disease.

It prevents proper communication between nerves and muscles, leading to fluctuating muscle weakness.

2️⃣ It doesn’t affect everyone the same way.

Symptoms vary from person to person they may include vision problems, speech difficulties, difficulty speaking or swallowing, severe fatigue, trouble breathing, or limited mobility.

3️⃣ Invisible and unpredictable symptoms

Symptoms can fluctuate throughout the day and worsen with physical effort or emotional stress.

4️⃣ Diagnosis can take time.

Because of the wide range of symptoms, it can take months or even years

to get a clear diagnosis, as is often the case with many rare diseases.

5️⃣ People can live with myasthenia gravis.

With proper medical care and a growing understanding of the condition, many people lead active, professional and social life 💪💚

📲 Stay connected: we’ll be sharing key facts to raise awareness about myasthenia gravis.

🔗 Sources:

AFM-Téléthon – Myasthénie auto-immune
• MSD Manuals – Myasthénie grave

05/06/2025

🎙️June – Myasthenia Gravis Awareness Month

🧠 Myasthenia gravis is a rare neuromuscular disease. It impairs the transmission between nerves and muscles, primarily causing as excessive fatigue and fluctuating, unpredictable muscle weakness.

❗Too little known, the symptoms of this disease vary from person to person and may also include:

👀 double vision

🗣 speech and swallowing difficulties

💪 trouble moving, or even breathing…

💚 This June, we stand in solidarity with all those affected by this invisible and often misunderstood condition

📲 Follow us throughout the month: as we share resources and key information to better understand this disease.

Because understanding is already helping.

🔗 Source: AFM-Téléthon

04/06/2025

A few days ago, we marked World Multiple Sclerosis (MS) Day.

At Ad Scientiam, our commitment is ongoing — and today, we’re proud to share some major news:

🌟 MSCopilot®, our class IIa Software as a Medical Device (SaMD) dedicated to the monitoring of people living with multiple sclerosis (MS), has received CE marking under the European Medical Device Regulation (EU MDR) 2017/745.

🔬 This certification confirms the safety, clinical performance and benefit of our digital solution, the result of over 10 years of clinical research in collaboration with expert centers and leading industry partners.

💡 This is a milestone for people living with MS, as well as for their families and the healthcare professionals who support them every day.

🙏 Thank you to everyone who made this achievement possible.

This is just the beginning.

30/05/2025

🔬 MS-DETECT
An international clinical study aimed at evaluating disability progression in Multiple Sclerosis using MSCopilot®.

🧠 Recently, we shared with you our work on MS and the projects we are conducting to improve the management of this disease.

📌 Today, let’s take a closer look at the MS-DETECT study.

🎯 Objective?

To evaluate the ability of MSCopilot® to detect the early and subtle signs of disability progression in people living with MS.

📊 Why is it important?

More than 300 patients will be followed for up to 24 months in their daily lives with MSCopilot®, in order to better understand the individual longitudinal trajectories of the disease.

🌍 7 countries involved:

United States, Canada, France, Germany, Spain, Italy, Denmark.

📲 Stay tuned for updates on this study!

20/03/2025

Does happiness have a real impact on our health?🧐

Happiness isn’t just an emotion, it has a direct impact on our health. Studies show that happy people have a lower risk of heart disease and a better-performing immune system (source: Harvard Health). 🌍

At Ad Scientiam we develop innovative solutions to improve the monitoring of patients with chronic or debilitating diseases. We are convinced that happiness and health are inseparable.

On World Happiness Day, let’s take a moment to celebrate everyone’s well-being!

👉 What’s your happiness score out of 10? Share it with us and let’s celebrate together! 💛✨

05/01/2024

👉At Ad Scientiam, we deliver innovative digital solutions that enhance the patient journey.
We leverage their feedback to continuously improve our work!🌟

08/12/2023

Our fully decentralized ME&MGopen study took flight nine months ago.
🌟Today, we proudly report the inclusion of 202 patients, with 186 in the USA 🇺🇸 and 23 in Canada 🇨🇦.
👉Stay tuned for ongoing updates on the study's progress.

🇨🇦 🇺🇸

01/12/2023

📣Big news! We are thrilled to announce that Ad Scientiam and Ceres Brain Therapeutics are launching a joint research program to develop new digital biomarkers for Creatine Transporter Deficiency Syndrome.
Ad Scientiam, a global leader in digital biomarkers and Ceres Brain Therapeutics, a biotech company developing a drug candidate for a rare neurological disease, the Creatine Transporter Deficiency Syndrome, join forces to develop new digital biomarkers to optimize future clinical trials.

🔗Read the full press release here : https://www.adscientiam.com/en/ad-scientiam-et-ceres-brain-therapeutics-unissent-leurs-forces-pour-developper-des-biomarqueurs-digitaux-innovants-dans-le-deficit-du-transporteur-de-creatine/?fbclid=IwAR0MzuBtJECwr5YaKPuji3YFn_m95Z2czRJBEv3ljAxlLW_aBIbQiufGo7k

👉Stay tuned for exciting advancements in the field of neurological research and digital health!

Adresse

21-23 Rue Albert Bayet
Paris
75013

Heures d'ouverture

Lundi	09:30 - 18:00
Mardi	09:30 - 18:00
Mercredi	09:30 - 18:00
Jeudi	09:30 - 18:00
Vendredi	09:30 - 18:00

Site Web

https://www.adscientiam.com/en/

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Ad Scientiam_US publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.